Oral arguments today in a federal appeals court case brought by the AHA, Association of American Medical Colleges, America’s Essential Hospitals and three hospital organizations to challenge a nearly 30% reduction to Medicare payments for 340B drugs focused on procedure issues. However, as evidenced by questions from the judges, the court seemed most interested in whether the Medicare statute expressly precludes judicial review of the Department of Health and Human Services’ actions. The attorney representing the government argued that the Congress clearly intended to preclude review, arguing that the specific section relied on to make the payment reduction was “mushed up together” in the section of the law that authorized preclusion. The attorney for the AHA and other plaintiffs argued forcefully that evidence of preclusion must be clear and convincing and that the preclusion provision identifies only specific statutory sections that are shielded from review, including sections added to law after the addition of the section at issue in the case. There also was discussion of whether plaintiffs had adequately presented their claims to the Centers for Medicare & Medicaid Services and whether CMS had the legal authority to reduce reimbursement to section 340B hospitals by almost 30% under the section of the statute establishing the reimbursement methodology for separately payable outpatient prospective payment system drugs. The AHA hopes for a ruling from the court sometime this summer. To listen to a recording of today’s oral arguments, click here
 

Headline
The AHA drafted and filed an amicus brief June 17 in the 5th U.S. Circuit Court of Appeals in a case regarding Medicaid financing and provider taxes filed by…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The AHA May 27 filed an amicus brief in the 7th U.S. Circuit Court of Appeals supporting the dismissal of an online tracking lawsuit against a member hospital…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…